54 Danbury Rd, Suite #197
Ridgefield, CT 06877
Rx Analytic (RxA) is developing a transformative nanopharmaceutical dosage form, a nano inorganic-encapsulation, which is expected to have broad impact on the treatment of respiratory diseases such as asthma, lung cancer, and lower respiratory tract infection. Our inorganic nanometer scale technology is designed to optimize the pharmacokinetics of inhaled therapies with a choice of an anti-inflammatory coating for repurposing Asthma drugs, an anti-neoplastic coating for lung cancer chemotherapies, and an anti-microbial coating for acute respiratory tract infection medications. RxA is an early stage startup seeking to build its network with companies interested in novel platform technologies.